Merck presents one-year BRUNELLO results for remigromig in diabetic macular edema at AAO 2026

Merck presented one-year results from the pivotal Phase 2b/3 BRUNELLO study evaluating remigromig, a tri-specific Wnt pathway agonist, in adults with diabetic macular edema at AAO 2026.

Detected & updated continuously · Source: Nebula